Corrigendum to Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis Kidney International Reports, Volume 8, Issue 1, January 2023, Pages 30–35

The authors regret that in Table 1, the mechanism of action for Atrasentan was incorrectly listed as “Dual ETA receptor/AT1 receptor antagonist.” The correct mechanism of action is “ETA receptor antagonist.”

The authors would like to apologize for any inconvenience caused.

DOI of original article: 10.1016/j.ekir.2022.10.004